WuXi AppTec enters into partnership with QIAGEN

WuXi AppTec Inc. today announced that it has entered into a partnership with QIAGEN to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases. QIAGEN will provide a complete portfolio of instrumentation, training, and consumables and WuXi AppTec will provide laboratory facilities and staff to execute the services. The laboratory will be located at WuXi AppTec's campus in Shanghai and will begin operating immediately.

Under the terms of the partnership agreement, WuXi AppTec will also work with QIAGEN to help develop biomarkers, assay panels, personalized healthcare diagnostics, and other products that QIAGEN intends to bring to market. WuXi AppTec will use QIAGEN's technologies for a broad range of applications in support of drug discovery and development on behalf of the company's and QIAGEN's customers. WuXi AppTec and QIAGEN will also co-promote each other's services to their respective customers. Both companies are working closely to identify additional opportunities to deepen their relationship.

"WuXi AppTec has long been interested in partnering with a premier international molecular biotechnology company like QIAGEN to support the development of our biomarker business," said Dr. Ge Li, Chairman and CEO of WuXi AppTec. "This partnership gives us access to innovative technologies and processes that will allow us to better serve our customers."

"We are very pleased to have entered into this partnership with WuXi AppTec, a global leader in providing integrated research and development services to the pharmaceutical industry," said Dr. Victor Shi, President, Asia Pacific of QIAGEN. "In doing so, we have created what we believe to be the first laboratory of its kind in Asia equipped with a standardized, fully integrated, automated sample and assay technology platform for drug discovery and development and molecular diagnostics in personalized healthcare and other areas. We believe that this partnership is a significant milestone in providing high-quality and complete automated solutions for the molecular biomarker testing industry."

SOURCE WuXi AppTec Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Qiagen. (2010, January 11). WuXi AppTec enters into partnership with QIAGEN. News-Medical. Retrieved on August 02, 2021 from https://www.news-medical.net/news/20100111/WuXi-AppTec-enters-into-partnership-with-QIAGEN.aspx.

  • MLA

    Qiagen. "WuXi AppTec enters into partnership with QIAGEN". News-Medical. 02 August 2021. <https://www.news-medical.net/news/20100111/WuXi-AppTec-enters-into-partnership-with-QIAGEN.aspx>.

  • Chicago

    Qiagen. "WuXi AppTec enters into partnership with QIAGEN". News-Medical. https://www.news-medical.net/news/20100111/WuXi-AppTec-enters-into-partnership-with-QIAGEN.aspx. (accessed August 02, 2021).

  • Harvard

    Qiagen. 2010. WuXi AppTec enters into partnership with QIAGEN. News-Medical, viewed 02 August 2021, https://www.news-medical.net/news/20100111/WuXi-AppTec-enters-into-partnership-with-QIAGEN.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
FDA approves QIAGEN’s therascreen EGFR test as companion diagnostic for NSCLC patients